6021^ Background: The EXTREME trial demonstrated that patients with R/M-SCCHN benefit
significantly from the addition of cetuximab to first-line platinum-based CT in relation to …

Background: Cetuximab and docetaxel have single-agent activity in squamous cell
carcinoma of the head and neck (SCCHN). The efficacy of their combination was evaluated …

Background The efficacy and safety of a novel combination of weekly paclitaxel and the
epidermal growth factor receptor (EGFR) monoclonal antibody cetuximab for the first-line …

Purpose This was an open, randomized, multicenter, phase I/II study to investigate the safety
and tolerability of cetuximab in the first-line treatment of recurrent/metastatic squamous cell …

Background The use of cetuximab in combination with platinum (P) plus 5-fluorouracil (F)
has previously been demonstrated to be effective in the treatment of metastatic squamous …

6032 Background: Platinum-based chemotherapy with cetuximab is the standard of care for
relapsed or metastatic squamous cell carcinoma of the head and neck (SCCHN). The aim of …

Purpose This multicenter phase II study was undertaken to define the efficacy and safety of
cetuximab, an antiepidermal growth factor receptor chimeric human and murine monoclonal …

Background Cetuximab in combination with platinum and 5-fluorouracil is the standard of
care in the first-line treatment of patients with recurrent/metastatic head and neck squamous …

6048 Background: Cetuximab and docetaxel are both active in squamous cell carcinoma of
the head and neck (SCCHN). We investigated the efficacy of cetuximab plus docetaxel as …

Background Cetuximab is effective in platinum-resistant recurrent or metastatic squamous-
cell carcinoma of the head and neck. We investigated the efficacy of cetuximab plus …